The latest report by IMARC, titled “Vaccine Adjuvants Market Report by Product Type (Adjuvant Emulsions, Pathogen Components, Particulate Adjuvants, Combination Adjuvants, and Others), Route of Administration (Oral, Intramuscular, Intranasal, Subcutaneous, Intradermal, and Others), Diseases (Cancer, Infectious Diseases, and Others), Application (Research, Commercial), and Region 2025-2033”, finds that the global vaccine adjuvants market size reached USD 1,107.0 Million in 2024. Vaccine adjuvants are compounds that improve the body’s immunogenic response against antigens. They increase the ability of the vaccines to induce long-term protection against infections. Presently, aluminum salts and MF59 are the only adjuvants found fit for human use. In recent years, the demand for vaccine adjuvants has escalated as they increase antibody titers, reduce required antigen doses, induce a rapid immune response and long-lasting memory, and enhance the immune response in the elderly and young children.
Global Vaccine Adjuvants Market Trends:
One of the primary factors driving the market is the rising incidences of infectious diseases and allergies, such as human immunodeficiency virus (HIV/AIDS), cancer, human papillomavirus (HPV), and tuberculosis. Additionally, the need for advanced treatment options for prevailing and emerging fatal diseases has increased the need to develop vaccines possessing long-lasting effects on immunization. Other than this, governments of numerous nations are taking initiatives for immunization and improvements in adjuvants for human consumption. They are also focusing on enhancing the healthcare infrastructure and increasing investments in research and development (R&D) of new therapeutics, which is creating a positive market outlook. Furthermore, with the sudden coronavirus (COVID-19) outburst, the demand for effective and safe vaccine adjuvants is constantly increasing. On account of these factors, IMARC Group expects the market value to reach USD 2,851.7 Million by 2033, expanding at a CAGR of 10.53% during the forecast period (2025-2033).
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Product Type, Route of Administration, Diseases, Application, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Adjuvatis, Agenus Inc., Croda International Plc, CSL Limited, Dynavax Technologies, InvivoGen, Novavax Inc., OZ Biosciences, Phibro Animal Health Corporation, SEPPIC, SPI Pharma, etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800